Effect Of Post Allogenic Stem Cell Transplant Cyclophosphamide On engraftment and relapse Compared with Other Regimen Of GVHD (graft versus host disease) Prophylaxis

Abstract

Graft-versus-host disease (GVHD) continues to compromise the overall success of allogeneic hematopoietic cell transplantation (HCT).Although rates and severity of acute GVHD have decreased with improvements in donor selection criteria, pharmacologic prophylaxes, and supportive care, rates of chronic GVHD have remained remarkably stable at 35% to 50% for many years.1 The median duration of systemic immunosuppressive treatment of chronic GVHD is; 2.5 years after bone marrow transplantation (BMT) and 3.5 years after mobilized blood cell transplantation.